TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Brief Summary: The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib.

Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
B: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: IMA901 plus GM-CSF added to sunitinib after single dose of cy; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Biological: GM-CSF, Drug: Cyclophosphamide, Drug: IMA901 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy, Sunitinib | Intervention Type: BIOLOGICAL; Name: GM-CSF; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: IMA901; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: A-immunotherapy; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa-2a, Drug: Interleukin-2 | Arm Label: B-follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Interferon Alfa-2a; Assigned to Arm(s): A-immunotherapy | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): A-immunotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy Study of Physiotherapy for Airway Clearance in Cystic Fibrosis. Randomized Controlled Trials in Single Subjects (N of 1 RCT's).
Brief Summary: The purpose of this study is to investigate individual efficacy in Physiotherapy for Airway Clearance, and to investigate user experience, i.e.utility value and preference.


Options:
A: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
B: Arm Label: HFCWO Arm; Type: EXPERIMENTAL; Interventions: Device: Airway clearance Device | Arm Label: CPT Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Airway clearance Device; Assigned to Arm(s): HFCWO Arm
C: Arm Label: Visit A; Type: ACTIVE_COMPARATOR; Interventions: Other: Rest period | Arm Label: Visit B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airway clearance session using the Active Cycle of Breathing Techniques (ACBT) | Intervention Type: PROCEDURE; Name: Airway clearance session using the Active Cycle of Breathing Techniques (ACBT); Assigned to Arm(s): Visit B | Intervention Type: OTHER; Name: Rest period; Assigned to Arm(s): Visit A
D: Arm Label: Physiotherapy techniques; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy | Intervention Type: OTHER; Name: Physiotherapy; Assigned to Arm(s): Physiotherapy techniques

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Baclofen for the Treatment of Alcohol Dependence - BACLAD
Brief Summary: There is first evidence from preclinical and clinical studies for the efficacy of the selective GABA-B receptor agonist baclofen in the treatment of alcohol dependence. The aim of this trial is to evaluate the efficacy and safety of individually titrated high-dose baclofen for relapse prevention in alcohol-dependent patients.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Baclofen 30mg/day | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Baclofen 75mg/day | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Baclofen 30mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Baclofen 75mg/day; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
B: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Benfotiamine; Type: EXPERIMENTAL; Interventions: Drug: Benfotiamine | Intervention Type: DRUG; Name: Benfotiamine; Assigned to Arm(s): Benfotiamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: Baclofen; Type: EXPERIMENTAL; Interventions: Drug: Baclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Baclofen; Assigned to Arm(s): Baclofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Baclofen | Intervention Type: DRUG; Name: Baclofen; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment
Brief Summary: The purpose of this study is to assess improvement in health related quality of life of fibromyalgia patients following 6 weeks of interdisciplinary treatment compared to the usual treatment.


Options:
A: Arm Label: Interdisciplinary treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary treatment, Behavioral: Interdisciplinary treatment of fibromyalgia | Arm Label: Usual treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interdisciplinary treatment; Assigned to Arm(s): Interdisciplinary treatment | Intervention Type: BEHAVIORAL; Name: Interdisciplinary treatment of fibromyalgia; Assigned to Arm(s): Interdisciplinary treatment
B: Arm Label: Pain Ed; Type: EXPERIMENTAL; Interventions: Behavioral: Pain Ed, Other: Usual Care | Arm Label: CBT for Pain; Type: EXPERIMENTAL; Interventions: Behavioral: CBT for Pain, Other: Usual Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Pain Ed; Assigned to Arm(s): Pain Ed | Intervention Type: BEHAVIORAL; Name: CBT for Pain; Assigned to Arm(s): CBT for Pain | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): CBT for Pain, Pain Ed, Usual Care
C: Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A
D: Arm Label: Lifestyles A; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyles A | Arm Label: Lifestyle B; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyles B | Arm Label: Lifestyles C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyles C | Intervention Type: BEHAVIORAL; Name: Lifestyles A; Assigned to Arm(s): Lifestyles A | Intervention Type: BEHAVIORAL; Name: Lifestyles B; Assigned to Arm(s): Lifestyle B | Intervention Type: BEHAVIORAL; Name: Lifestyles C; Assigned to Arm(s): Lifestyles C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment
Brief Summary: The purpose of this study is to assess improvement in health related quality of life of fibromyalgia patients following 6 weeks of interdisciplinary treatment compared to the usual treatment.


Options:
A: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A
B: Arm Label: Tai Chi Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi Intervention | Arm Label: Control Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control Intervention | Intervention Type: BEHAVIORAL; Name: Tai Chi Intervention; Assigned to Arm(s): Tai Chi Intervention | Intervention Type: BEHAVIORAL; Name: Control Intervention; Assigned to Arm(s): Control Intervention
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Attention Control Counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Attention Control Counseling; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): 2
D: Arm Label: Interdisciplinary treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary treatment, Behavioral: Interdisciplinary treatment of fibromyalgia | Arm Label: Usual treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interdisciplinary treatment; Assigned to Arm(s): Interdisciplinary treatment | Intervention Type: BEHAVIORAL; Name: Interdisciplinary treatment of fibromyalgia; Assigned to Arm(s): Interdisciplinary treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment
Brief Summary: The purpose of this study is to assess improvement in health related quality of life of fibromyalgia patients following 6 weeks of interdisciplinary treatment compared to the usual treatment.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Attention Control Counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Attention Control Counseling; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): 2
B: Arm Label: Interdisciplinary treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary treatment, Behavioral: Interdisciplinary treatment of fibromyalgia | Arm Label: Usual treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interdisciplinary treatment; Assigned to Arm(s): Interdisciplinary treatment | Intervention Type: BEHAVIORAL; Name: Interdisciplinary treatment of fibromyalgia; Assigned to Arm(s): Interdisciplinary treatment
C: Arm Label: Strength training; Type: EXPERIMENTAL; Interventions: Behavioral: Strength training | Arm Label: Aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic exercise | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): Strength training | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise
D: Intervention Type: BEHAVIORAL; Name: self-management program; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®
Brief Summary: Rotavirus, sometimes called the "stomach flu," is the most common cause of severe diarrhea in children. Vaccines can prevent many types of infections and work by causing the body to make proteins called antibodies that fight infection. For some vaccines, more than one vaccination is needed so that the body will make enough antibodies to fight infection. The vaccines (RotaTeq® or Rotarix® oral vaccines) given in this study are recommended for infants by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). These vaccines require either 2 or 3 vaccinations to be effective. Healthy infants between 6 weeks and 14 weeks, 6 days of age at Visit 1 will participate for about 10-12 months. Study procedures include reaction assessment and blood sample.


Options:
A: Arm Label: PLACEBO-ROTARIX-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: ROTARIX-PLACEBO-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP, PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP
B: Arm Label: Group 1, RotaTeq® x 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq® | Arm Label: Group 5, Rotarix®, RotaTeq® x2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 4, Rotarix® x 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix® | Arm Label: Group 2, RotaTeq®, Rotarix® x 2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 3, RotaTeq® x 2, Rotarix®; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Intervention Type: BIOLOGICAL; Name: Rotarix®; Assigned to Arm(s): Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 4, Rotarix® x 2, Group 5, Rotarix®, RotaTeq® x2 | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1, RotaTeq® x 3, Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 5, Rotarix®, RotaTeq® x2
C: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Gemcitabine Plus Oxaliplatin (GEMOX) With or Without Cetuximab in Locally Advanced and Metastatic Biliary Tract Cancer (BTC)
Brief Summary: The primary objective is to investigate the objective response rate in patients receiving GEMOX (gemcitabine plus oxaliplatin) plus cetuximab as first line treatment in advanced or metastatic unresectable BTC biliary tract cancer compared to patients receiving the same chemotherapy without cetuximab. The secondary objectives include the exploration of the effect of the multimodality strategy on progression-free and overall survival, biomarker prediction, and toxicity.


Options:
A: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: cediranib, Drug: gemcitabine | Arm Label: Arm A; Type: PLACEBO_COMPARATOR; Interventions: Drug: gemcitabine, Drug: cisplatin, Drug: Placebo | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): B
B: Arm Label: Arm A- p-Gemox; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab plus GEMOX chemotherapy, Drug: GEMOX chemotherapy | Arm Label: Arm B-GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: GEMOX chemotherapy | Intervention Type: DRUG; Name: Panitumumab plus GEMOX chemotherapy; Assigned to Arm(s): Arm A- p-Gemox | Intervention Type: DRUG; Name: GEMOX chemotherapy; Assigned to Arm(s): Arm A- p-Gemox, Arm B-GEMOX
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemox, Cetuximab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Gemox, Cetuximab | Intervention Type: DRUG; Name: Gemox, Cetuximab; Assigned to Arm(s): 1, 2
D: Arm Label: GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine, oxaliplatin | Arm Label: E-GEMOX; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, gemcitabine, oxaliplatin | Intervention Type: DRUG; Name: gemcitabine, oxaliplatin; Assigned to Arm(s): GEMOX | Intervention Type: DRUG; Name: cetuximab, gemcitabine, oxaliplatin; Assigned to Arm(s): E-GEMOX

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Randomized Placebo-Controlled Trial of Somatostatin in Association With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding
Brief Summary: Background: Efficacy of endoscopic variceal sclerotherapy in achieving initial control of acute variceal bleeding and five-day haemostasis has been shown to significantly improve when vasoactive drug is added. However, there is limited data whether addition of somatostatin, to endoscopic variceal ligation (EVL) improves the efficacy of EVL.

Aim: To compare EVL plus somatostatin versus EVL plus placebo in control of acute variceal bleeding.

Patients and methods: Consecutive cirrhotic patients with acute variceal bleeding from esophageal varices were enrolled in the trial. After emergency EVL, patients were randomized to receive either somatostatin (250 mcg/hr) or placebo infusion. Primary endpoint was treatment failure within 5 days. Treatment failure was defined as fresh hematemesis ≥2 hour after start of therapy or death.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Experimental group | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Control group
B: Arm Label: EVL plus Somatostatin; Type: EXPERIMENTAL; Interventions: Drug: Somatostatin | Arm Label: EVL plus Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Somatostatin; Assigned to Arm(s): EVL plus Somatostatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EVL plus Placebo
C: Arm Label: Erythromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythromycin | Arm Label: Placebo Group endoscopic therapy; Type: NO_INTERVENTION; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): Erythromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Group endoscopic therapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Intervention Type: PROCEDURE; Name: red blood cell transfusion; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Brief Summary: Use of PTH (1-84) a recombinant hormone in 25 µg or 50 µg doses for the treatment of adults with hypoparathyroidism. The use of PTH (1-84) should result in a decrease of calcium and vitamin D supplements.


Options:
A: Arm Label: 25 µg dose; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Arm Label: 50 µg dose; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Intervention Type: DRUG; Name: NPSP558; Assigned to Arm(s): 25 µg dose, 50 µg dose
B: Intervention Type: DRUG; Name: Synthetic Human Parathyroid Hormone 1-34; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50, 75, 100 mcg NPSP558; Type: EXPERIMENTAL; Interventions: Drug: NPSP558 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: NPSP558; Assigned to Arm(s): 50, 75, 100 mcg NPSP558
D: Arm Label: a: PTH (1-84) 100 ug s.c.inj. once a day; Type: ACTIVE_COMPARATOR; Interventions: Drug: a: PTH (1-84) | Arm Label: b: placebo 100 ug s.c. inj. once a day; Type: PLACEBO_COMPARATOR; Interventions: Drug: b:placebo | Intervention Type: DRUG; Name: a: PTH (1-84); Assigned to Arm(s): a: PTH (1-84) 100 ug s.c.inj. once a day | Intervention Type: DRUG; Name: b:placebo; Assigned to Arm(s): b: placebo 100 ug s.c. inj. once a day

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study of the Time Course of Response to Biphentin® Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom Setting
Brief Summary: The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting. Biphentin methylphenidate hydrochloride extended release capsule has been formulated for daily dosing to provide treatment of a child with Attention deficit hyperactivity disorder (ADHD) for the substantial day.


Options:
A: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
B: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsule, Drug: Placebo | Arm Label: Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsule, Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsule; Assigned to Arm(s): Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo), Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo), Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CONCERTA (methylphenidate HCl) / Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Placebo/ CONCERTA (methylphenidate HCl) | Intervention Type: DRUG; Name: Placebo/ CONCERTA (methylphenidate HCl); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CONCERTA (methylphenidate HCl) / Placebo; Assigned to Arm(s): 1

Answer: C